Programme Topics
The 13th World Conference on Lung Cancer will highlight recent important advances in lung cancer in the areas
of prevention, early detection, molecular biology, biotechnology and therapy.
Preliminary topics include:
- Adenocarcinoma: Multidisciplinary Classification
- Adjuvant Therapies in Early Disease Management
- Angiogenesis in Lung Cancer
- Biomarkers for Early Detection
- Biorepository Issues
- Bringing Quality of Life Assessment
into the Mainstream of Lung Cancer
Management - Chemoprevention
- Clinical Trial Designs with Biomarkers to Incorporate or Validate Clinical or Lab Selection
- Controlling Adverse Effects of Treatment in Lung Cancer
- Cutting Edge in “OMICS” Research for Lung Cancer
- Debate – Stereotactic radiotherapy for Stage I NSCLC: Should it be Regarded as the Standard of Care for Inoperable Tumors and Are We Ready to Replace Surgery?
- Debate – What is the Role of Adjuvant Radiation Therapy in Resected N2 Non- Small Cell Lung Cancer Patients
- Developing Small Molecule Therapeutics for Chemoprevention
- Early Detection of Lung Cancer
- EGFR and VEGF Pathways
- Emerging Field of Lung Cancer Research
- Emerging Operative Techniques in Early Stage Lung Cancer
- Established Targets for NSCLCMulti- Targeted Agents and Drug Combination
- Genetics and Epigenetics in Lung Carcinogenesis
- Identifying Cancer Stem Cells
- Image Guided Biopsy
- Image Guided Procedures
- Implementing IGRT in Clinical Practice
- Implementing Radiation and Systemic
Therapy for Stage III Non-Small Cell
Lung Cancers - Issues with Modeling Approached to Mortality Reduction Benefit
- Locally Advanced Lung Cancer; Role of Surgery & Mediastinal Evaluations
- Lung Cancer Biomarkers
- Management of Malignant Pleural Effusions
- Minimally Invasive Non-Surgical Non-Small Cell Lung Cancer Staging
- Molecular Predictors of Response and Resistance to EGFR TKIs
- New Insights in the Pathogenesis and Treatment of Malignant mesothelioma
- New Pathological Staging
- Novel Agents in Clinical Trials for Prevention
- Novel Targets Beyond EGFR and VEGF
- Novel Technologies
- Open Challenges in the Management of Advanced NSCLC
- Optimal Therapy for Resectable Lung Cancer
- Pathological Diagnosis and Molecular Analysis of Small and Cytological Specimens
- Peri-operative Pain Control
- Pleural Mesothelioma : Bridging the Present with the Future
- Predictive or Prognostic Factors in Chemotherapy
- Progress with Neoadjuvant Window of Opportunity Trials
- Risk Stratified Approaches to Prevention of Lung Cancer
- Role of Advocacy Groups in Lung Cancer
- Role of the Chest Physician in a Multidisciplinary Lung Cancer Clinic
- Role of the Pathologist in the
Development of Predictive Markers for
Therapy Benefit - SCLC : An Orphan Disease ?
- Signal Transduction Inhibitors – Biology and Activity
- Specialized Surgical Expertise: Indications, Results
- Staging and Follow-up of Lung Cancer
- Statistical Issues in Early Drug Development
- Supportive Care Optimization as a Target
- Targets for Chemoprevention
- Tobacco Control
- Trial Designs in the Bioinformatics Age
- Update on Hematopoietic Growth Factors in Lung Cancer Management
- Women and Lung Cancer
